IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors

  IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell
                        BioSciences Board of Directors

PR Newswire

NEW YORK, Oct. 29, 2012

NEW YORK, Oct. 29, 2012 /PRNewswire/ --IntelliCell BioSciences, Inc.
("Company") (SVFC) announced today that Myron Z. Holubiak has joined the
IntelliCell Board of Directors. Mr. Holubiak is an accomplished biotech and
pharmaceutical senior executive with over 30 years of industry experience
including directing Roche Laboratories, a $2.8 billion dollar company with
over 3,500 employees, as its President. Mr. Holubiak also serves as Director
for Ventrus BioSciences, Inc. and Chairman of the Board for BioScrip, Inc.

IntelliCell's Chairman and CEO, Dr. Steven Victor, stated, "Our Company is
very pleased to announce today that Myron Holubiak is joining our Board of
Directors. He is bringing a wealth of industry experience and accomplishments
to our executive team. I look forward to working with him to assist
IntelliCell in its growth strategies as the Company continues its thought
leadership role as a preeminent Regenerative Medicine organization."

Said Mr. Holubiak, "The decades of scientific research into regenerative
medicine is now showing dramatic results and fulfilling the promise we all had
hoped for.

"Dr. Victor's pioneering efforts in the advancement of the science and his
innovations in the use of ultrasonic cavitation is now setting the standard
for the harvest of autologous stromal vascular fractions that are
demonstrating promise in clinical efficacy.

"I am pleased to join the board of IntelliCell. The company is committed to
far reaching clinical research in the treatment of osteoarthritis, diabetic
ulcers, bone and dermal conditions where regenerative processes are
desperately needed.

"I look forward to participating in the growth of IntelliCell at such an
exciting time."

About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the
expanding regenerative medical markets using adult autologous vascular cells
(SVC's) derived from the blood vessels in the adult adipose tissue.
IntelliCell BioSciences has developed its own patent pending protocol to
separate adult autologous vascular cells from adipose tissue without the use
of enzymes. IntelliCell will also be seeking to develop technology-licensing
agreements with technology developers, universities, and international
business entities.

Forward-LookingStatements
Certain statements set forth in this press release constitute "forward-looking
statements." Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future results,
performance or achievements, and may contain the words "estimate," "project,"
"intend," "forecast," "anticipate," "plan," "planning," "expect," "believe,"
"will likely," "will reach," "will change," "will soon," "should," "could,"
"would," "may," "can" or words or expressions of similar meaning. Such
statements are not guarantees of future performance and are subject to risks
and uncertainties that could cause the company's actual results and financial
position to differ materially from those included within the forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including those relating to the Company's ability to grow its business. Actual
results may differ materially from the results predicted and reported results
should not be considered as an indication of future performance. The potential
risks and uncertainties include, among others, the Company's limited operating
history, the limited financial resources, domestic or global economic
conditions, activities of competitors and the presence of new or additional
competition, and changes in Federal or State laws. More information about the
potential factors that could affect the Company's business and financial
results is included in the Company's filings, available via the United States
Securities and Exchange Commission.

Contacts:
IntelliCell BioSciences, Inc.
Robert J. Sexauer
Email Contact: rsexauer@intellicellbiosciences.com 
(646) 576-8706 

SOURCE IntelliCell BioSciences, Inc.
 
Press spacebar to pause and continue. Press esc to stop.